Community post

Adaptive Phage Therapeutics and the Mayo Clinic have announced a collaboration to commercialize a phage susceptibility test. The test will enable rapid identification of patient-specific phages for therapy (based on screening hundreds of candidates selected from APT's PhageBank), and will be offered for worldwide commercial availability by Mayo Clinic Laboratories.